Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.16 USD | -2.17% | +0.71% | +18.34% |
Mar. 01 | Artivion Files Mixed Shelf | MT |
Feb. 22 | Artivion Insider Sold Shares Worth $1,358,818, According to a Recent SEC Filing | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.34% | 883M | B- | ||
+3.26% | 197B | C+ | ||
+5.79% | 116B | C | ||
+1.48% | 71.49B | A | ||
+11.77% | 53.47B | B- | ||
+18.31% | 48.42B | B- | ||
+6.33% | 43.64B | B+ | ||
+12.38% | 28.97B | A- | ||
+9.76% | 28.47B | B | ||
+10.35% | 27.78B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Artivion, Inc. - Nyse
- Ratings Artivion, Inc.